POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

After 60 years new drug for lupus from Canada approved in U.S.

Christian Fernsby |
People living with lupus will soon have access to a breakthrough treatment discovered by an Albertan life sciences entrepreneur, who is creating a more globally competitive drug commercialization industry in Canada.

Article continues below

Dr. Robert Foster, an adjunct professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, discovered voclosporin in the early 1990s after founding a start-up drug company in his Edmonton basement.

It would take nearly 30 years, but the drug would earn the approval of the U.S. Food and Drug Administration to treat lupus-related kidney disease. Voclosporin was approved by the FDA earlier this year.

"This is a homegrown Canadian success story. The FDA doesn't approve Canadian drugs often," Foster said. " Voclosporin will improve people's lives; it's a breakthrough for people living with lupus."

Medical treatments for lupus are rare. Volcosporin is only the second treatment to come to market to treat lupus in more than 60 years. It is not yet approved for use in Canada. While Foster understands possible frustration from Canadians unable to access the new lupus therapy, he expressed hope and optimism for the future of Canada's life sciences sector.

Since developing voclosporin, Foster has become CEO of Hepion Pharmaceuticals - a US company with its research and development headquartered in Edmonton. Hepion is now researching a treatment for fatty liver disease, and has joined forces with Alberta's leading drug commercialization accelerator - Applied Pharmaceutical Innovation (API).

What to read next

Rich, poor have huge mortality gap in U.S.: 14.6 years
Global life expectancy on rise, major inequalities persist
Washing hands - a good investment in your health